Results 61 to 70 of about 46,287 (147)

Efficacy and safety of liposomal irinotecan plus nimotuzumab in immune checkpoint inhibitor-refractory recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase II trial. [PDF]

EClinicalMedicine
He S, Bei WX, Lu N, Zhao ZY, Ye Y, Chen C, Tang L, Liu L, Lv S, Xiang YQ, Wang L.   +10 more
europepmc   +1 more source

Impact of prior conventional irinotecan use on nanoliposomal irinotecan efficacy in advanced pancreatic cancer: a meta-analysis. [PDF]

ESMO Open
Lee S, Correa TL, Birda V, Roshan K, Peters ML, Modest AM, Keko M, Bockorny B.   +7 more
europepmc   +1 more source

A single-arm phase II trial of <i>UGT1A1</i> genotype-guided high-dose irinotecan rechallenge in refractory metastatic colorectal cancer. [PDF]

Front Oncol
Kim H, Hong J, Kong SY, Choi MK.
europepmc   +1 more source

Epigallocatechin-3-Gallate, the green tea polyphenol suppresses expression of CD31 and VEGFR2 and enhances the chemotherapeutic potential of irinotecan in AOM/DSS model of colorectal cancer in mice. [PDF]

J Egypt Natl Canc Inst
Rahman SS, Baruah S, Akhtara N, Nath JK, Bharali MK.   +4 more
europepmc   +1 more source

Circulating tumour DNA to guide rechallenge with cetuximab plus irinotecan in RAS/BRAF wild-type metastatic colorectal cancer: A nonrandomised clinical trial. [PDF]

Clin Transl Med
Wang DS, Chen WC, Ren C, Wang FH, Wang ZQ, Luo HY, Wang F, Tan Q, Li YH.   +8 more
europepmc   +1 more source

Overcoming Resistance: Targeting Survivin-Driven Apoptotic Resistance Restores Irinotecan Sensitivity in <i>TP53</i>-Mutant Colorectal Cancer. [PDF]

Cancers (Basel)
Dumut DC, Xu YZ, Verelli D, Das V, Hajduch M, De Sanctis JB, Radzioch D.   +6 more
europepmc   +1 more source

Clinical Implications of <i>UGT1A1</i> Polymorphisms in Anticancer Therapy: An Updated Review. [PDF]

Pharmaceutics
Vitale SR, Drago M, Martorana F, Conti C, Massimino M, Stella S, Tomarchio C, Vigneri P, Manzella L.   +8 more
europepmc   +1 more source

Modulation of Drug Resistance and Apoptotic Pathways Underlies the Enhanced Antitumor Effect of Ellagic Acid-Irinotecan Combination in Glioma. [PDF]

Int J Mol Sci
Biltekin B, Çetin A.
europepmc   +1 more source

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx). [PDF]

Br J Clin Pharmacol
Chauhan D, Dello Russo C, Thompson J, Hughes DA, Payne K, Tsakiroglou M, Ross P, Chauhan R, Jenkinson S, Keen J, Harding S, Lau E, Braun M, Agarwal R, Adams R, Rolf E, Al-Sheikhli F, Mitchell S, Hammond R, Roberts R, Cairns L, Heggarty S, Graham J, Mencel J, Pirmohamed M.   +24 more
europepmc   +1 more source

Design, Synthesis and Biological Evaluation of Novel SN38 Based Albumin-Binding Peptide-Drug Conjugates in Pancreatic Ductal Adenocarcinoma. [PDF]

Pharmaceutics
Su Y, Lu Y, Yu J, Jin C, Chen Y, Lu W, Ding J.   +6 more
europepmc   +1 more source